<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939029</url>
  </required_header>
  <id_info>
    <org_study_id>09-002581</org_study_id>
    <secondary_id>CA140125</secondary_id>
    <secondary_id>09-001763</secondary_id>
    <nct_id>NCT00939029</nct_id>
  </id_info>
  <brief_title>Highdose Nicotine Patch Therapy for Smokeless Tobacco Use</brief_title>
  <official_title>Highdose Nicotine Patch Therapy for Smokeless Tobacco Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Smokeless tobacco use (&quot;chewing&quot;) is associated with negative health effects. To date, no
      medications have been shown to help chewers quit long-term. High dose nicotine patch therapy
      may improve the chances that chewers can quit for good. If found to be effective, chewers may
      use this treatment to help them quit and reduce their risk for negative health effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 8.2 million (3.3%) of Americans ≥ 12 years of age are current smokeless tobacco
      (ST) users, and the prevalence of ST use has increased over the past three years. ST is
      increasingly being promoted as a harm reduction strategy for cigarette smoking, and two of
      the world's largest cigarette manufacturers have entered the ST market. ST use is estimated
      to be the greatest exogenous source of human exposure to cancer-causing nitrosamines. ST has
      been associated with oral and extra-oral cancer as well as cardiovascular and cerebrovascular
      mortality.

      A need for efficacious interventions exists as 64% of ST users report the desire to quit.
      However, no pharmacotherapy has proven efficacy for increasing long-term (&gt; 6 months) tobacco
      abstinence rates among ST users compared to placebo. New pharmacotherapies, drug
      combinations, and improved dosing of existing pharmacotherapies are needed. Previous research
      with nicotine patches for ST users using standard doses (up to 21 mg/day) have not increased
      long-term abstinence rates. However, studies of higher dose nicotine patch therapy (up to 63
      mg/day) in ST users have demonstrated a dose-dependent reduction in tobacco withdrawal
      symptoms as well as preliminary evidence of increased long-term (&gt; 6 months) abstinence rates
      compared to lower doses. The purpose of this study is to evaluate the efficacy of high dose
      nicotine patch therapy (42 mg/day) for increasing the 7-day point prevalence and prolonged
      all tobacco and ST abstinence rates at end-of-treatment (week 8), 12 and 24 weeks compared to
      placebo in ST users who use ≥ 3 cans/pouches per week when all subjects receive behavioral
      treatment for tobacco dependence. To accomplish our aims, we will randomize 60 ST users in a
      clinical pilot study. The work will be conducted at the Mayo Clinic in Rochester, MN.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End of Treatment (Week 8) Point Prevalence Abstinence</measure>
    <time_frame>weeks 8</time_frame>
    <description>7 day point prevalence abstinence at the end of treatment, biochemically confirmed by urinary anabasine &lt; 2 ng per ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Point-prevalence Abstinence at 3 Months</measure>
    <time_frame>week 12</time_frame>
    <description>7 day point prevalence abstinence from tobacco at 3 months, biochemically confirmed using urinary anabasine &lt; 2 ng per ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Point-prevalence Abstinence at 6 Months</measure>
    <time_frame>week 24</time_frame>
    <description>7 day point prevalence abstinence from all tobacco at 6 months, biochemically confirmed using urinary anabasine &lt; 2 ng per ml.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Smokeless Tobacco Use</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 patches (containing non active ingredients) per day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine replacement therapy (nicotine patches)</intervention_name>
    <description>2- 21 mg patches per day for 8 weeks</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo NRT</intervention_name>
    <description>2 placebo patches (containing no active ingredient)per day for 8 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. are at least 18 years of age and at most 55 years of age;

          2. report daily ST use for the past 12 months;

          3. identify ST as their primary tobacco product;

          4. use an average of ≥ 3 cans/pouches per week;

          5. are in general good health (determined by medical history and screening physical
             examination);

          6. have been provided with, understand, and have signed the informed consent.

        Exclusion Criteria:

          1. are currently using (past 30 days) any other behavioral or pharmacologic tobacco
             treatment program;

          2. are currently pregnant or lactating;

          3. have had unstable angina, myocardial infarction, or coronary angioplasty within the
             past 3 months;

          4. have a history of arrhythmia or an abnormal tracing on the baseline EKG;

          5. have a blood pressure of greater than 140/90 or a pulse of more than 110 beats per
             minute;

          6. have a history of severe skin allergies or dermatoses;

          7. have a history of intolerance to nicotine patches;

          8. have another member of their household already participating in this study;

          9. are taking a medication known to interact with nicotine (i.e., clozapine);

         10. are taking any prescription medication for depression or asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon O Ebbert, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ebbert JO, Croghan IT, Schroeder DR, Hurt RD. A randomized phase II clinical trial of high-dose nicotine patch therapy for smokeless tobacco users. Nicotine Tob Res. 2013 Dec;15(12):2037-44. doi: 10.1093/ntr/ntt097. Epub 2013 Jul 19.</citation>
    <PMID>23873976</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2009</study_first_submitted>
  <study_first_submitted_qc>July 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2009</study_first_posted>
  <results_first_submitted>March 25, 2014</results_first_submitted>
  <results_first_submitted_qc>March 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2014</results_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Jon Ebbert</investigator_full_name>
    <investigator_title>Priniciple Investigator</investigator_title>
  </responsible_party>
  <keyword>tobacco use</keyword>
  <keyword>smokeless tobacco</keyword>
  <keyword>chewing tobacco</keyword>
  <keyword>snuff</keyword>
  <keyword>nicotine replacement</keyword>
  <keyword>tobacco dependence</keyword>
  <keyword>tobacco cessation</keyword>
  <keyword>tobacco abstinence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Lobeline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active</title>
          <description>2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
nicotine replacement therapy (nicotine patches): 2- 21 mg patches per day for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>2 patches (containing non active ingredients) per day for 8 weeks
placebo NRT: 2 placebo patches (containing no active ingredient)per day for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention to treat analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
nicotine replacement therapy (nicotine patches): 2- 21 mg patches per day for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>2 patches (containing non active ingredients) per day for 8 weeks
placebo NRT: 2 placebo patches (containing no active ingredient)per day for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.2" spread="9.1"/>
                    <measurement group_id="B2" value="35.3" spread="9.5"/>
                    <measurement group_id="B3" value="37.2" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian, Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smokeless tobacco use</title>
          <description>Average cans/pouches of smokeless tobacco used per week over the last month prior to the baseline visit</description>
          <units>cans or pouches per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="1.8"/>
                    <measurement group_id="B2" value="4.0" spread="1.3"/>
                    <measurement group_id="B3" value="4.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>End of Treatment (Week 8) Point Prevalence Abstinence</title>
        <description>7 day point prevalence abstinence at the end of treatment, biochemically confirmed by urinary anabasine &lt; 2 ng per ml</description>
        <time_frame>weeks 8</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
nicotine replacement therapy (nicotine patches): 2- 21 mg patches per day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 patches (containing non active ingredients) per day for 8 weeks
placebo NRT: 2 placebo patches (containing no active ingredient)per day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>End of Treatment (Week 8) Point Prevalence Abstinence</title>
          <description>7 day point prevalence abstinence at the end of treatment, biochemically confirmed by urinary anabasine &lt; 2 ng per ml</description>
          <population>intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>1 tailed p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>7.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Point-prevalence Abstinence at 3 Months</title>
        <description>7 day point prevalence abstinence from tobacco at 3 months, biochemically confirmed using urinary anabasine &lt; 2 ng per ml</description>
        <time_frame>week 12</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
nicotine replacement therapy (nicotine patches): 2- 21 mg patches per day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 patches (containing non active ingredients) per day for 8 weeks
placebo NRT: 2 placebo patches (containing no active ingredient)per day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Point-prevalence Abstinence at 3 Months</title>
          <description>7 day point prevalence abstinence from tobacco at 3 months, biochemically confirmed using urinary anabasine &lt; 2 ng per ml</description>
          <population>intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>1 tailed</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>11.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Point-prevalence Abstinence at 6 Months</title>
        <description>7 day point prevalence abstinence from all tobacco at 6 months, biochemically confirmed using urinary anabasine &lt; 2 ng per ml.</description>
        <time_frame>week 24</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
nicotine replacement therapy (nicotine patches): 2- 21 mg patches per day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 patches (containing non active ingredients) per day for 8 weeks
placebo NRT: 2 placebo patches (containing no active ingredient)per day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Point-prevalence Abstinence at 6 Months</title>
          <description>7 day point prevalence abstinence from all tobacco at 6 months, biochemically confirmed using urinary anabasine &lt; 2 ng per ml.</description>
          <population>intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.087</p_value>
            <p_value_desc>1 tailed</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
nicotine replacement therapy (nicotine patches): 2- 21 mg patches per day for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>2 patches (containing non active ingredients) per day for 8 weeks
placebo NRT: 2 placebo patches (containing no active ingredient)per day for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Infection was post band saw injury trauma. This occurred 4 months after subject had discontinued the patches and is not considered to be related to study drug (nicotine patches)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>sleep disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>patch site reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jon Ebbert</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-4736</phone>
      <email>ebbert.jon@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

